Legis Daily

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019

USA116th CongressS-474| Senate 
| Updated: 2/13/2019
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (12)
Tammy Duckworth (Democratic)Catherine Cortez Masto (Democratic)Kirsten E. Gillibrand (Democratic)Christopher A. Coons (Democratic)Thomas R. Carper (Democratic)Amy Klobuchar (Democratic)Jon Tester (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Benjamin L. Cardin (Democratic)Robert Menendez (Democratic)Gary C. Peters (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 13, 2019
Introduced in Senate
Feb 13, 2019
Read twice and referred to the Committee on Finance.
  • February 13, 2019
    Introduced in Senate


  • February 13, 2019
    Read twice and referred to the Committee on Finance.

Health

Civil actions and liabilityCorporate finance and managementGovernment information and archivesInflation and pricesMarketing and advertisingPrescription drugsResearch and development

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019

USA116th CongressS-474| Senate 
| Updated: 2/13/2019
Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 13, 2019
Introduced in Senate
Feb 13, 2019
Read twice and referred to the Committee on Finance.
  • February 13, 2019
    Introduced in Senate


  • February 13, 2019
    Read twice and referred to the Committee on Finance.
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (12)
Tammy Duckworth (Democratic)Catherine Cortez Masto (Democratic)Kirsten E. Gillibrand (Democratic)Christopher A. Coons (Democratic)Thomas R. Carper (Democratic)Amy Klobuchar (Democratic)Jon Tester (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Benjamin L. Cardin (Democratic)Robert Menendez (Democratic)Gary C. Peters (Democratic)

Finance Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Civil actions and liabilityCorporate finance and managementGovernment information and archivesInflation and pricesMarketing and advertisingPrescription drugsResearch and development